Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach.
Klotz LV, Hoffmann H, Shah R, Eichhorn F, Gruenewald C, Bulut EL, Griffo R, Muley T, Christopoulos P, Baum P, Huber P, Safi S, Kriegsmann M, Thomas M, Bischoff H, Winter H, Eichhorn ME. Klotz LV, et al. Among authors: christopoulos p. Transl Lung Cancer Res. 2022 Nov;11(11):2230-2242. doi: 10.21037/tlcr-22-199. Transl Lung Cancer Res. 2022. PMID: 36519024 Free PMC article.
AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients.
Schneider MA, Christopoulos P, Muley T, Warth A, Klingmueller U, Thomas M, Herth FJ, Dienemann H, Mueller NS, Theis F, Meister M. Schneider MA, et al. Among authors: christopoulos p. Int J Oncol. 2017 Feb;50(2):365-372. doi: 10.3892/ijo.2017.3834. Epub 2017 Jan 2. Int J Oncol. 2017. PMID: 28101582 Free PMC article.
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.
Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, Ristau J, Buchhalter I, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Warth A, Bischoff H, Schirmacher P, Stenzinger A, Thomas M. Christopoulos P, et al. Int J Cancer. 2018 Jun 15;142(12):2589-2598. doi: 10.1002/ijc.31275. Epub 2018 Jan 24. Int J Cancer. 2018. PMID: 29363116
Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.
Buchhalter I, Rempel E, Endris V, Allgäuer M, Neumann O, Volckmar AL, Kirchner M, Leichsenring J, Lier A, von Winterfeld M, Penzel R, Christopoulos P, Thomas M, Fröhling S, Schirmacher P, Budczies J, Stenzinger A. Buchhalter I, et al. Among authors: christopoulos p. Int J Cancer. 2019 Feb 15;144(4):848-858. doi: 10.1002/ijc.31878. Epub 2018 Dec 4. Int J Cancer. 2019. PMID: 30238975
Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma.
Christopoulos P, Kirchner M, Bozorgmehr F, Endris V, Elsayed M, Budczies J, Ristau J, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Lasitschka F, Bischoff H, Sotillo R, Schirmacher P, Thomas M, Stenzinger A. Christopoulos P, et al. Int J Cancer. 2019 Jan 1;144(1):190-199. doi: 10.1002/ijc.31893. Epub 2018 Oct 30. Int J Cancer. 2019. PMID: 30255938
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.
Allgäuer M, Budczies J, Christopoulos P, Endris V, Lier A, Rempel E, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Fröhling S, Penzel R, Thomas M, Schirmacher P, Stenzinger A. Allgäuer M, et al. Among authors: christopoulos p. Transl Lung Cancer Res. 2018 Dec;7(6):703-715. doi: 10.21037/tlcr.2018.08.14. Transl Lung Cancer Res. 2018. PMID: 30505715 Free PMC article. Review.
313 results